Z

Zymeworks
D

ZYME

12.950
USD
0.09
(0.70%)
مغلق
حجم التداول
11,467
الربح لكل سهم
-2
العائد الربحي
-
P/E
-8
حجم السوق
901,020,635
أصول ذات صلة
A
ARCT
0.350
(2.80%)
12.850 USD
C
CRSP
0.520
(1.38%)
38.220 USD
I
INO
0.03000
(1.59%)
1.91500 USD
S
SLNO
0.190
(0.25%)
75.200 USD
V
VCEL
1.025
(2.70%)
38.935 USD
المزيد
الأخبار المقالات

العنوان: Zymeworks

القطاع: Healthcare
الصناعة: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.